Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Martins (Sao Paulo, Brazil), A. Da Silva (Rio de Janeiro, Brazil), P. Rocco (Rio de Janeiro, Brazil), V. Capelozzi (Sao Paulo, Brazil). FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis. 1197

Member's Comments

No comment yet.

Related content which might interest you: The role of chemokines and cytokines in lung fibrosis Source: Eur Respir Rev 2008; 17: 151-156 Year: 2008 Interleukin-17 (IL-17) contributes to silica-induced alveolitis but is not essential in fibrosis development Source: Eur Respir J 2006; 28: Suppl. 50, 675s Year: 2006 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by regulating inflammatory cytokines in bronchoalveolar fluid Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013 Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis Source: Eur Respir J 2012; 39: 141-148 Year: 2012 Renin is an angiotensin-independent profibrotic mediator: role in pulmonary fibrosis Source: Eur Respir J 2011; 39: 141-148 Year: 2012 M2 polarized alveolar macrophages in pulmonary fibrosis Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Alveolar macrophage oxidative and pro-inflammatory cytokine activity in lung sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 332s Year: 2005 The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 IL-36? – a key mediator of neutrophilic inflammation in chronic obstructive pulmonary disease Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease Year: 2021 Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004 PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 459s Year: 2003 Neutrophil airway influx by platelet-activating factor in asthma: role of adhesion molecules and LTB4 expression Source: Eur Respir J 2003; 22: 290-297 Year: 2003 Anti-inflammatory cytokines in cystic fibrosis lung disease Source: Eur Respir J 2006; 28: 581-587 Year: 2006 COPD is associated with reduced pulmonary interstitial expression of pentraxin-3 Source: Eur Respir J 2012; 39: 830-838 Year: 2012 Role of IL23 in the development of fibrotic interstitial lung disease Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Role of IL-33 signaling in pollutant-induced allergic airway inflammation Source: International Congress 2018 – Translational models of the immunopathology that underlies airway obstructive diseases Year: 2018 Disturbance of pro-inflammatory cytokine production in patients with cystic fibrosis lung disease Source: Eur Respir J 2005; 26: Suppl. 49, 404s Year: 2005